Ecchymosis adverse event reports that record this term

Kind of term: MedDRA preferred term

What a report is

A report is not proof that the drug was the cause of the event.

FDA says:

Adverse event reports submitted to FDA do not undergo extensive validation or verification. Therefore, a causal relationship cannot be established between product and reactions listed in a report. While a suspected relationship may exist, it is not medically validated and should not be the sole source of information for clinical decision making or other assumptions about the safety or efficacy of a product. Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.
Source: openFDA, Drug Adverse Event Overview, section "Responsible use of the data". The site read the page on 2 Oct 2026. The data have the reports that FDA received through 30 Jun 2026.

FDA also says:

There is no certainty that the reported event (adverse event or medication error) was actually due to the product. FDA does not require that a causal relationship between a product and event be proven, and reports do not always contain enough detail to properly evaluate an event. The information in these reports has not been scientifically or otherwise verified as to a cause and effect relationship and cannot be used to estimate the incidence of these events.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated.
Source: openFDA, Response of the drug event API (meta.disclaimer). The site read the page on 2 Oct 2026.

Not medical advice. This site counts what was reported to FDA. Questions about a medicine or device belong with a pharmacist or clinician.

Reports on file

From January 2004 to June 2026, FDA received 6,736 adverse event reports that record the MedDRA preferred term Ecchymosis. The person who codes a report selects the term that agrees best with the description of the reporter.

FDA received 287 reports in the 12 months to June 2026 and 293 in the 12 months before. FDA releases FAERS data every quarter, so the newest months are not complete. They grow in later releases.

By reports in the 12 months to June 2026, this term was number 1,243 of 1,436 reaction terms with a page. Of the 1,332,454 drug reports that FDA received in the 12 months to June 2026, 287 (under 0.1%) record this term. Reports for patients 75 and over were 22.7% of the reports that record this term and 9.5% of all drug reports.

The number of people who use the product is not in the data. A count is not a rate.

MedDRA

The Medical Dictionary for Regulatory Activities. The person who codes a report selects the preferred term that agrees best with the description of the reporter. FDA does not publish the description.

Data version

openFDA FAERS release of 29 Oct 2026. Reports received through 30 Jun 2026.

Drugs in these reports

The table has the 74 drug pages with 25 or more reports that record this term. The rows are in order of name. A drug page with fewer reports for this term is not in the table. The counts are the counts that the site keeps for each reaction term, and a count can be lower than the count of FDA.

FDA says:

Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Importantly, the AEMS data by themselves are not an indicator of the safety profile of the drug or biologic.
Source: FDA, FDA Adverse Event Monitoring System (AEMS) Public Dashboard. Content current as of 11 Mar 2026. The site read the page on 2 Oct 2026.

Drugs that the reports with the term Ecchymosis name as a suspect product, in order of name
Drug	Class	Reports with this term
Abatacept	Selective T cell costimulation modulator	28
Acetaminophen		28
Acetylsalicylic Acid		134
Actemra	Interleukin-6 receptor antagonist	88
Albuterol	beta2-Adrenergic agonist	26
Alendronate sodium	Bisphosphonate	61
Allopurinol	Xanthine oxidase inhibitor	26
Alteplase		33
Alvesco		28
Amlodipine	Calcium channel blocker	32
Apixaban	Factor Xa inhibitor	54
Arava	Antirheumatic agent	34
Aredia		69
Arixtra	Factor Xa inhibitor	27
Aspirin	Nonsteroidal anti-inflammatory drug	265
Avastin	Vascular endothelial growth factor inhibitor	35
Breo Ellipta	Corticosteroid	28
Ciprofloxacin	Fluoroquinolone antibacterial	30
Clopidogrel	P2Y12 platelet inhibitor	150
Clopidogrel bisulfate	P2Y12 platelet inhibitor	46
Coumadin		166
Cyclophosphamide	Alkylating drug	43
Cymbalta		28
Cytarabine	Nucleoside metabolic inhibitor	46
Desoximetasone	Corticosteroid	35
Dexamethasone	Corticosteroid	75
Digoxin	Cardiac glycoside	43
Eliquis	Factor Xa inhibitor	118
Eltrombopag olamine	Thrombopoietin receptor agonist	32
Enbrel	Tumor necrosis factor blocker	103
Enoxaparin sodium	Low molecular weight heparin	60
Exjade	Iron chelator	25
Forteo	Parathyroid hormone analog	43
Fosamax	Bisphosphonate	165
Fosamax Plus D		33
Furosemide	Loop diuretic	33
Heparin		50
Humira		90
Hydroxychloroquine sulfate	Antimalarial	28
Ibrutinib (form s4)	Kinase inhibitor	56
Ibuprofen	Nonsteroidal anti-inflammatory drug	46
Imbruvica	Kinase inhibitor	142
Inflectra	Tumor necrosis factor blocker	27
Infliximab	Tumor necrosis factor blocker	33
Jakafi	Janus kinase inhibitor	44
Kardegic		30
Levofloxacin	Fluoroquinolone antibacterial	44
Lovenox	Low molecular weight heparin	45
Lyrica		31
Methotrexate	Folate analog metabolic inhibitor	121
Methotrexate sodium	Folate analog metabolic inhibitor	35
Mycophenolate mofetil	Antimetabolite immunosuppressant	35
Nasonex	Corticosteroid	28
Nplate	Thrombopoietin receptor agonist	59
Plavix	P2Y12 platelet inhibitor	97
Pradaxa	Direct thrombin inhibitor	132
Prednisolone	Corticosteroid	35
Prednisone	Corticosteroid	153
Pulmicort Turbuhaler		27
Revlimid	Thalidomide analog	58
Rituxan	CD20-directed cytolytic antibody	25
Rituximab	CD20-directed cytolytic antibody	66
Rivaroxaban	Factor Xa inhibitor	38
Sertraline	Serotonin reuptake inhibitor	32
Singulair	Leukotriene receptor antagonist	46
Tacrolimus	Calcineurin inhibitor immunosuppressant	34
Vioxx		45
Warfarin	Vitamin K antagonist	162
Warfarin sodium	Vitamin K antagonist	170
Xarelto	Factor Xa inhibitor	409
Xeljanz	Janus kinase inhibitor	28
Xiaflex		54
Xolair	Anti-IgE	25
Zometa		105

The page of each drug has the count of each reaction term in its reaction lookup.

Drug classes in these reports

The table has the 52 pharmacologic classes with 25 or more reports that record this term. The rows are in order of name.

FDA says:

Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Importantly, the AEMS data by themselves are not an indicator of the safety profile of the drug or biologic.
Source: FDA, FDA Adverse Event Monitoring System (AEMS) Public Dashboard. Content current as of 11 Mar 2026. The site read the page on 2 Oct 2026.

Pharmacologic classes of the drugs that the reports with the term Ecchymosis name, in order of name
Class	Reports with this term
Alkylating drug	66
Angiotensin 2 receptor blocker	31
Angiotensin converting enzyme inhibitor	27
Anti-epileptic agent	65
Anti-IgE	37
Anticholinergic	39
Antimalarial	45
Antimetabolite immunosuppressant	41
Antirheumatic agent	47
Atypical antipsychotic	61
Azole antifungal	35
BCL-2 inhibitor	31
Benzodiazepine	52
beta-Adrenergic blocker	43
beta2-Adrenergic agonist	48
Bisphosphonate	252
Calcineurin inhibitor immunosuppressant	53
Calcium channel blocker	34
Cardiac glycoside	43
CD20-directed cytolytic antibody	103
Corticosteroid	431
Direct thrombin inhibitor	134
Factor Xa inhibitor	652
Fluoroquinolone antibacterial	78
Folate analog metabolic inhibitor	159
HMG-CoA reductase inhibitor	58
Interleukin-6 receptor antagonist	110
Iron chelator	27
Janus kinase inhibitor	98
Kinase inhibitor	331
Leukotriene receptor antagonist	54
Loop diuretic	42
Low molecular weight heparin	105
Macrolide antimicrobial	25
Nonsteroidal anti-inflammatory drug	395
Nucleoside metabolic inhibitor	116
Opioid agonist	79
P2Y12 platelet inhibitor	332
Parathyroid hormone analog	43
Penicillin-class antibacterial	30
Platinum-based drug	34
Proteasome inhibitor	28
Proton pump inhibitor	49
Selective T cell costimulation modulator	51
Serotonin and norepinephrine reuptake inhibitor	28
Serotonin reuptake inhibitor	143
Thalidomide analog	64
Thrombopoietin receptor agonist	118
Tumor necrosis factor blocker	220
Vascular endothelial growth factor inhibitor	43
Vitamin K antagonist	332
Xanthine oxidase inhibitor	26

A class with many reports in all has many reports for almost every term.

Reports by month

Reports that record Ecchymosis, by month, five years to June 2026

FDA releases FAERS data every quarter, so the newest months are not complete. They grow in later releases.

Patients in these reports

Age of the patient in the reports that record Ecchymosis
Age	Reports	Share
Under 2	40	0.6%
2 to 11	136	2%
12 to 17	91	1.4%
18 to 44	778	11.5%
45 to 64	1,408	20.9%
65 to 74	1,085	16.1%
75 and over	1,529	22.7%
Age not given	1,669	24.8%

Sex of the patient in the reports that record Ecchymosis
Sex	Reports	Share
Female	3,771	56%
Male	2,425	36%
Unknown or not given	540	8%

Age and sex are as the report gives them. 47.1% of these reports give the United States as the country.

Terms near this one

These are the next terms in the A to Z list. The links are for navigation.

Official pages

MedWatch Online Voluntary Reporting FormThe online form of FDA for a voluntary report.
MedWatch: The FDA Safety Information and Adverse Event Reporting ProgramThe page of the FDA program that receives reports about drugs and devices.
FDA Adverse Event Monitoring System (AEMS) Public DashboardThe public dashboard of FDA for adverse event reports on drugs and biologics.

The site checked these addresses on 2 Oct 2026. The links open in a new tab.

Cite this page

Reported Reactions. Ecchymosis: adverse event reports that record this term. https://reportedreactions.com/reaction/ecchymosis/ Source: U.S. Food and Drug Administration, openFDA Drug Adverse Event (FAERS) files, release of 29 Oct 2026. Reports received through 30 Jun 2026.

Where the data come from

The counts come from the openFDA Drug Adverse Event (FAERS) bulk files, release of 29 Oct 2026. The files have the reports that FDA received through 30 Jun 2026. A drug name is the name on the report. The site matches it to a brand name or a generic name of the National Drug Code Directory of 2 Nov 2026. A class is the pharmacologic class (EPC) of the FDA label.

The count has the reports with each spelling of one MedDRA preferred term. The site does not publish a report narrative, a lot number, a detail of a patient or the identity of a reporter. The record of FDA is the authority. See how the site counts reports, the data sources and the corrections page.

Questions

What does Ecchymosis mean in an adverse event report?

It is a MedDRA preferred term. FDA codes the description of a reporter with the MedDRA dictionary. The openFDA files do not have the description itself, and this site does not show it.

Does a drug in the table mean that the drug was responsible for this reaction?

No. FDA says:

No individual drug is connected to any individual reaction.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

When a report lists multiple drugs and multiple reactions, there is no way to conclude from the data therein that a given drug is responsible for a given reaction.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

What does this page tell a person who has this symptom?

This page gives counts of reports. It cannot assess a person. A pharmacist or a clinician can assess a person.

If this is a medical emergency, please call 911.
Source: FDA, MedWatch Online Voluntary Reporting Form. The site read the page on 2 Oct 2026.

To the top of the page